Revolution Medicines

KRAS
#Award #KRAS #Oncology #Pancreatic cancer #Revolution Medicines

$1 million Stephenson Global Prize honours pioneering KRAS research

Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research.   His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#FDA #Oncology #Pancreatic cancer #Revolution Medicines

FDA approves RAS-targeted drug for metastatic pancreatic cancer

The US Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC).  It is approved in patients who have received at least one prior systemic therapy or who are not candidates for multiagent… Read More

#Editor's Choice #News #Regulatory